The ethical choice
For immediate release

Results of Major NHS Anxiety Study Released at Annual MindTech Symposium

The first clinical results of a major NHS study on how Cranial Electrotherapy Stimulation (CES) provided by the Alpha-Stim AID medical device can help IAPT patients with anxiety disorders, are to be presented by Richard Morriss, Professor of Psychiatry and Community Mental Health at the University of Nottingham. Professor Morriss, who wrote the protocol for study, will be presenting his findings on 7th December at the annual NIHR MindTech Symposium at the Royal College of Physicians.

The results of a major NHS study on how Cranial Electrotherapy Stimulation (CES) provided by the Alpha-Stim AID medical device can help IAPT (Improving Access to Psychological Therapy) patients with anxiety disorders will be announced at the forthcoming NIHR MindTech National Symposium this December. [1] The study was carried out to establish the clinical and cost effectiveness of this new form of treatment for those who have already tried basic psychological therapies unsuccessfully at IAPT.

CES is already widely used in the US, particularly by the American government, to help those suffering with PTSD, and since the study began, IAPT services in Leicester City and Leicestershire have started using the Alpha-Stim as part of their program to successfully treat many patients with anxiety. The results of trial will hopefully help to give many thousand more patients the chance to try this unique drug-free treatment that can be easily and safely used at home. Professor Morriss will discuss the changes in anxiety, insomnia and depression reported by patients during the trial, and the possible clinical and cost benefits to patients and the NHS of introducing the treatment across IAPT services in England.

One in four people in the UK will experience a mental health problem in any given year [2] and the IAPT program was introduced by the NHS in 2008 to help facilitate better access to treatment for patients throughout England suffering from anxiety and depression. Over 900,000 patients now use IAPT services each year.

The Alpha-Stim AID device works on the same electrical pathways that naturally occur in the brain and stimulates the nerve cells in the brain stem, the control centre of the brain. 98 percent of the synaptic communication in the brain is electrical rather than chemical and the treatment encourages the production of alpha-waves in the brain. It also stimulates the brain cells to trigger a reaction to produce Serotonin. Anti-depressant drugs (SSRI’s) do the same, but cranial electrotherapy stimulation does this without any lasting side-effects. Its positive effects are also cumulative, suggesting that the Alpha-Stim may bring about a permanent positive change in our neurological make-up.

The NHS study involved a sample of 161 patients and each patient’s results were measured for 24 weeks. The treatment procedure involved 60-minute self-directed Alpha-Stim AID CES treatment sessions undertaken at the participant’s home, on a daily basis for 6 weeks for all participants. Following 6 weeks of Alpha-Stim AID CES treatment, participants had the option to receive a further 6 weeks of treatment and were then measured at 24 weeks after a minimum period of 12 weeks without treatment to see if the changes seen during the active treatment weeks had been maintained. The study started in October last year with the final patient measurements due to be taken in December of this year.

The Alpha-Stim AID retails for £549 or is available on a buy-to-rent scheme from £51 a month. For more information please visit www.alpha-stim.co.uk or call 01487 208041.


NOTES TO EDITORS


References
[1] Professor Richard Morriss, University of Nottingham, ‘Clinical and cost effectiveness of Alpha-Stim AID Cranial Electrotherapy Stimulations (CES); a naturalistic study in patients with a primary working diagnosis of moderate-to-severe generalised anxiety disorder who did not improve with low intensity psychological therapy intervention’, September 2016.

About Richard Morriss, Professor of Psychiatry at Nottingham University
Professor Richard Morriss is a Consultant in General Adult and Community Psychiatry with Nottinghamshire Healthcare NHS Trust and Professor of Psychiatry and Community Mental Health at the University of Nottingham. He trained in psychiatry in Leeds, Johns Hopkins Hospital in Baltimore United States, Oxford and Manchester. He has a MD from University of Leeds.

Professor Morriss has clinical interests in mood disorders, somatization and primary care psychiatry. His research interests are in the management of bipolar affective disorder, depression and medically unexplained symptoms in primary and secondary care settings.

He was also a member of the NICE Guideline Development Group (GDG) for Bipolar Disorder and is currently a member of the NICE mental health panel.


ENDS

PR Newsroom - The Microcurrent Site: Alpha-Stim
Further information
For more information about Alpha-Stim AID, case studies or product and lifestyle images, please contact:
Ian & Jenny Liddle, Excellart, 01450 219 246
info@excellart.co.uk, www.facebook.com/Excellart, www.twitter.com/excellart

Previous Release
Next Release
Home
About Us
Marketing & Design
PR Newsroom
Public Relations
Training & Advice
Contact Us
PR Newsroom
Events:
West Midlands Vegan Festival
Experts:
Max Wiseberg (airborne allergies)
Howard Carter (bite prevention)
Daniel Brash (pharmacist)
Julie Silver (nutritional therapist)
Martin Fodor (green & eco issues)
Natural Health & Beauty:
HayMax
incognito
Enterosgel
Cisca Saltpipe

Qu-Chi
HealthCare4All
Alpha-Stim
Food:
Julie Silver
+44 (0) 1450 219246